Patients with any stage of renal disease should not receive the MR gadolinium contrast agent Omniscan, to help prevent a rare and life-threatening skin disease according to new, comprehensive MR Safe Practice Guidelines from the American College of Radiology.
Link to detailed guidelines here-
No comments:
Post a Comment